InsiderTradesSIGMA

InsidersTradesSigma

← Executives ★ Sign in to follow

DA

Dr Anne Beal

BOARD MEMBER

Cumul. flow

0

Total declarations

0

Company

—

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

Insider track record

Other

Disclosed buys

0

Disclosed sells

0

T+90 hit rate

69%

T+90 mean return

+7.1%

Across 16 buy signals with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Explore the complete record of transactions filed by Dr Anne Beal. Insider active across 1 company, notably GSK plc. Aggregated, 28 reports have been logged. Activity tracked since 20 June 2023. The latest transaction was filed on 22 June 2026 (Purchase). Regulator: RNS (LSE). All data is accessible without signup.

Declarations28 total

●

Independent Non-Executive DirectorExecutives22 Jun 2026GSK plc

£37,76530RNS ↗

745 shares@ £50.69080.0001% mcap94.8% of flowNew York Stock Exchange (XNYS)RNS:9632737-3

Ideal exit: 19 Mar 2027 (T+270)

●

Independent Non-Executive DirectorExecutives22 Jun 2026GSK plc

£37824RNS ↗

745 shares@ £0.50690.0000% mcap18.1% of flowNew York Stock Exchange (XNYS)RNS:1cabaef6-2e05-4f58-a412-24a2f7509642-3

Ideal exit: 19 Mar 2027 (T+270)

●

Independent Non-Executive DirectorExecutives9 Apr 2026GSK plc

32 shares@ £0.58940.0000% mcap1.1% of flowNew York Stock Exchange (XNYS)RNS:ca89baf1-aabf-4020-b0fe-d5c65c1b3a57-13

Ideal exit: 4 Jan 2027 (T+270)

●

Independent Non-Executive DirectorExecutives20 Mar 2026GSK plc

£10212RNS ↗

196 shares@ £0.5180.0000% mcap6.0% of flowNew York Stock Exchange (XNYS)RNS:c2055913-103f-4927-b6f8-8f0835af9e8e-4

Ideal exit: 15 Dec 2026 (T+270)

●

Independent Non-Executive DirectorExecutives9 Jan 2026GSK plc

31 shares@ £0.50420.9% of flowNew York Stock Exchange (XNYS)RNS:07b8fade-09b6-4441-a582-c78ac4e1b6b3-37

Ideal exit: 6 Oct 2026 (T+270)

●

Independent Non-Executive DirectorExecutives19 Dec 2025GSK plc

201 shares@ £0.48565.7% of flowNew York Stock Exchange (XNYS)RNS:5a98a0c7-d756-450b-83e9-f26937fe1a0f-3

Ideal exit: 15 Sept 2026 (T+270)

●

Independent Non-Executive DirectorExecutives10 Oct 2025GSK plc

34 shares@ £0.43741.0% of flowNew York Stock Exchange (XNYS)RNS:5859068-28

Ideal exit: 7 Jul 2026 (T+270)

●

Independent Non-Executive DirectorExecutives19 Sept 2025GSK plc

240 shares@ £0.40746.6% of flowNew York Stock Exchange (XNYS)RNS:5830475-4

Ideal exit: 16 Jun 2026 (T+270)

●

Independent Non-Executive DirectorExecutives11 Jul 2025GSK plc

35 shares@ £0.38540.9% of flowNew York Stock Exchange (XNYS)RNS:5737340-35

Ideal exit: 7 Apr 2026 (T+270)

●

Independent Non-Executive DirectorExecutives20 Jun 2025GSK plc

257 shares@ £0.37897.3% of flowNew York Stock Exchange (XNYS)RNS:5708028-5

Ideal exit: 17 Mar 2026 (T+270)

●

Independent Non-Executive DirectorExecutives20 Jun 2025GSK plc

257 shares@ £0.37897.3% of flowNew York Stock Exchange (XNYS)RNS:5707630-5

Ideal exit: 17 Mar 2026 (T+270)

●

Independent Non-Executive DirectorExecutives11 Apr 2025GSK plc

22 shares@ £0.34140.6% of flowNew York Stock Exchange (XNYS)RNS:5617047-3

Ideal exit: 6 Jan 2026 (T+270)

●

Independent Non-Executive DirectorExecutives25 Mar 2025GSK plc

£37610RNS ↗

970 shares@ £0.388128.9% of flowNew York Stock Exchange (XNYS)RNS:5593269-1

●

Independent Non-Executive DirectorExecutives20 Mar 2025GSK plc

249 shares@ £0.392713.4% of flowNew York Stock Exchange (XNYS)RNS:5584787-5

Ideal exit: 15 Dec 2025 (T+270)

●

Independent Non-Executive DirectorExecutives10 Jan 2025GSK plc

18 shares@ £0.33330.8% of flowNew York Stock Exchange (XNYS)RNS:5498728-19

Ideal exit: 7 Oct 2025 (T+270)

●

Independent Non-Executive DirectorExecutives20 Dec 2024GSK plc

271 shares@ £0.338112.7% of flowNew York Stock Exchange (XNYS)RNS:5479029-5

Ideal exit: 16 Sept 2025 (T+270)

●

Independent Non-Executive DirectorExecutives11 Oct 2024GSK plc

14 shares@ £0.39071.0% of flowNew York Stock Exchange (XNYS)RNS:5388451-3

Ideal exit: 8 Jul 2025 (T+270)

●

Independent Non-Executive DirectorExecutives23 Sept 2024GSK plc

224 shares@ £0.410117.3% of flowNew York Stock Exchange (XNYS)RNS:5362280-4

Ideal exit: 20 Jun 2025 (T+270)

●

Independent Non-Executive DirectorExecutives12 Jul 2024GSK plc

12 shares@ £0.39331.1% of flowNew York Stock Exchange (XNYS)RNS:5266837-13

Ideal exit: 8 Apr 2025 (T+270)

●

Independent Non-Executive DirectorExecutives21 Jun 2024GSK plc

225 shares@ £0.407620.8% of flowNew York Stock Exchange (XNYS)RNS:5235239-4

Ideal exit: 18 Mar 2025 (T+270)

●

Independent Non-Executive DirectorExecutives12 Apr 2024GSK plc

9 shares@ £0.410.8% of flowNew York Stock Exchange (XNYS)RNS:5143847-27

Ideal exit: 7 Jan 2025 (T+270)

●

Independent Non-Executive DirectorExecutives20 Mar 2024GSK plc

219 shares@ £0.41926.6% of flowNew York Stock Exchange (XNYS)RNS:5116598-5

Ideal exit: 15 Dec 2024 (T+270)

●

Independent Non-Executive DirectorExecutives12 Jan 2024GSK plc

6 shares@ £0.40170.7% of flowNew York Stock Exchange (XNYS)RNS:5034561-26

Ideal exit: 8 Oct 2024 (T+270)

●

Independent Non-Executive DirectorExecutives20 Dec 2023GSK plc

227 shares@ £0.366232.9% of flowNew York Stock Exchange (XNYS)RNS:5012405-5

Ideal exit: 15 Sept 2024 (T+270)

●

Independent Non-Executive DirectorExecutives13 Oct 2023GSK plc

4 shares@ £0.370.6% of flowNew York Stock Exchange (XNYS)RNS:4939502-5

Ideal exit: 9 Jul 2024 (T+270)

25 of 28 declarations

About Dr Anne Beal

Dr Anne Beal is a declarant who has made 28 filings in total. In her most recent filings, she purchased a total of 45471 euros worth of shares in GSK plc, with the last transaction recorded on June 24, 2026, where she bought for 43512.42 euros. Other transactions include purchases of varying amounts, as well as an other type transaction on March 28, 2025, for 450.26 euros.